SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : 1000% returns are cool !!! -- Ignore unavailable to you. Want to Upgrade?

To: If only I'd held who wrote (3134)7/25/2000 12:43:07 PM
From: PL Wilson  Read Replies (1) | Respond to of 3326
 
I own GNTA In my LT account.This could get big.Genasense treatment reduced Bcl-2 protein by 97% in breast cancer cells, and combined use with doxorubicin yielded a highly synergistic anticancer effect. Doxorubicin, a member of the anthracycline class of compounds, is one of the most widely prescribed anticancer drugs currently in use. The drug comprises a standard of first-line care for many diseases, including breast cancer, leukemia, and lymphoma.Genasense Has been through Phase I,II trials for saftey on humans,also has a phase III and a fast track.Good luck



To: If only I'd held who wrote (3134)8/7/2000 11:48:33 AM
From: Wes Stevens  Respond to of 3326
 
11:32 ET Genta, Inc. (GNTA) 6 17/32 +1 3/32 (+20.1%): Company receives notice from the FDA that its lead anticancer compound has been granted designation as an Orphan Drug.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News